口服danegaptide治疗非增殖性糖尿病视网膜病变的临床前与临床评估
研究在临床前动物模型和人视网膜微血管内皮细胞中评估口服gap junction调节剂danegaptide对视网膜血管通透性的调控作用,并报告一项1b期临床试验的安全性与早期疗效数据。该试验纳入24例非增殖性糖尿病视网膜病变伴轻度中心型黄斑水肿患者,未发现与口服danegaptide相关的严重不良事件,支持开展更大规模临床试验验证疗效。
要点
- 口服danegaptide通过connexin-43机制改善内血视网膜屏障功能。
- danegaptide可拮抗VEGF对人视网膜微血管内皮细胞的通透性作用。
- 1b期试验24例患者中未发现与danegaptide相关的严重不良事件。
核心结论
- 口服danegaptide在临床前模型中改善内血视网膜屏障功能,1b期试验显示安全性良好并支持进一步开展疗效试验。
研究设计与样本
- 临床前动物疾病模型及人视网膜微血管内皮细胞体外研究,联合一项1b期临床试验。
- 1b期临床试验纳入24例非增殖性糖尿病视网膜病变伴轻度中心型黄斑水肿患者。
主要发现
- danegaptide通过connexin-43机制并作为VEGF功能性拮抗剂改善内血视网膜屏障功能。
- bulk RNA测序显示danegaptide减弱VEGF对人视网膜微血管内皮细胞中TNFSF15的抑制。
- 用小干扰RNA靶向抑制TNFSF15或用中和抗体抑制其活性,可阻止体外VEGF诱导的通透性和体内新生血管病变发展。
临床怎么用
- 口服danegaptide可能为非增殖性糖尿病视网膜病变提供非侵入性治疗选择,但需更大规模临床试验验证疗效。
局限性
- 1b期临床试验为早期阶段、样本量24例,主要报告安全性与早期疗效数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Nonproliferative diabetic retinopathy (NPDR) is a serious and vision-threatening manifestation of diabetic eye disease. Most patients with diabetic eye disease have NPDR. Intravitreal vascular endothelial growth factor (VEGF)-neutralizing agents are able to suppress increased vascular leakage caused by poor glycemic control and are fundamental in controlling progression to vision loss. However, despite the efficacy of such treatments, the invasive nature and short interval between injections have not yielded widespread adoption in patients with NPDR. Here, we describe the effect of an orally available medication, danegaptide, in regulating retinal vascular permeability in preclinical animal models of disease and report safety and early efficacy data from an early-stage phase 1b clinical trial in patients with NPDR and mild center-involved macular edema. As an orally available gap junction modifier, danegaptide improved inner blood-retina barrier (iBRB) function through a direct connexin-43 mechanism and by working as a functional antagonist of VEGF in human retinal microvascular endothelial cells. Bulk RNA sequencing showed that danegaptide attenuated the VEGF-induced suppression of TNFSF15, an endogenous antagonist of VEGF activity in human retinal microvascular endothelial cells. In addition, targeted suppression of TNFSF15 using small interfering RNA or inhibition of its activity using a neutralizing antibody prevented VEGF-induced permeability in vitro and neovascular lesion development in vivo. No serious adverse events related to oral danegaptide were found in an early-stage phase 1b clinical trial in 24 patients with NPDR and mild center-involved macular edema. These findings support larger clinical trials to test efficacy.
引用
- Hudson N, Porkoláb G, O'Callaghan J, et al. Preclinical and clinical evaluation of systemic danegaptide for the treatment of nonproliferative diabetic retinopathy. Sci Transl Med. 2026. PMID: 42777083. doi:10.1126/scitranslmed.aed8692
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。